Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Observational

Cardiac Structure and Function in Patients with Cystic Fibrosis

NCT06084468 · tracked via the Priya Life Science Denmark tracker
Phase
Observational
Started
2023-01-01
Last updated
2025-03-13

Condition(s) studied

Cystic FibrosisCystic Fibrosis-related DiabetesCystic Fibrosis, PulmonaryCystic Fibrosis of PancreasCystic Fibrosis Gastrointestinal DiseaseCystic Fibrosis Modifier 1Left Ventricular DysfunctionHeart FailureHeart Failure, SystolicHeart Failure, DiastolicMyocardial InfarctionStrokeHeart Diseases

Study summary

In a prospective observational cohort study (n = 100), the investigators aim to assess the correlation between cardiac biomarkers, advanced echocardiography and cystic fibrosis genotype and severity and determine whether these are prognostic markers of heart disease in patients suffering from cystic fibrosis (CF).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * CF diagnosis * Age ≥ 18 years Exclusion Criteria: * Prior lung transplant * Inability to cooperate * Inability to understand and sign informed consent

Primary outcome measure(s)

  • Rate of cardiovascular mortality — 2, 5 and 10 year follow-up
  • Incidence of myocardial infarction — 2, 5 and 10 year follow-up
  • Incidence of coronary revascularization (percutaneous coronary intervention/coronary artery bypass graft) — 2, 5 and 10 year follow-up
  • Incidence of heart failure — 2, 5 and 10 year follow-up

Trial sites (2)

FacilityCityRegionStatus
Department of Cardiology, Herlev and Gentofte University Hospital, University of Copenhagen Hellerup Copenhagen
Department of Infectious Diseases, University Hospital of Copenhagen, Cystic Fibrosis Centre, Copenhagen, Denmark Copenhagen Denmark
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06084468 on ClinicalTrials.gov ↗ ← All trials in Denmark